Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
Juli Miller: Good morning, thank you for joining us.
Adaptimmune Therapeutics Plc (ADAP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Matrix Capital Management David Goel And Paul Ferri | 38,974,185 | $30,906,529 | 0.31% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 10,969,282 | $8,698,641 | 0.09% | |
| 3. | Partner Fund Management Christopher Medlock James | 10,423,135 | $8,265,546 | 0.49% | |
| 4. | BioImpact Capital Mpm Capital | 5,095,912 | $4,041,058 | 0.94% | |
| 5. | Tang Capital Management Kevin C. Tang | 4,387,238 | $3,479,080 | -16% | 0.32% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.29 | 39,000 | Officer | 96,000 | 2022-05-20 | Filing | |
| $0.79 | 12,600 | Director | 12,600 | 2021-06-01 | Filing | |
| $0.69 | 24,000 | Officer | 57,000 | 2020-12-14 | Filing | |
| $0.69 | 207,000 | Officer | 284,808 | 2020-12-14 | Filing | |
| $1.62 | 33,000 | Officer | 33,000 | 2020-06-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.67 | 30,080 | Officer, Director | 44,848 | 2024-01-17 | Filing | |
| $0.79 | 9,304 | Officer, Director | 14,104 | 2024-01-16 | Filing | |
| $0.67 | 12,967 | Officer | 19,257 | 2024-01-17 | Filing | |
| $0.67 | 5,309 | Officer | 7,785 | 2024-01-17 | Filing | |
| $0.79 | 2,287 | Officer | 3,363 | 2024-01-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,079,778 | $13,544,624 | 0.9% | |
| 2. | 15,912,140 | $12,618,327 | 0.01% | |
| 3. | 12,086,915 | $9,584,924 | 0.31% | |
| 4. | 5,555,461 | $4,405,481 | 2.16% | |
| 5. | 4,697,954 | $3,725,478 | 0% |
News See All
15 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the 15 top performing European stocks so far in 2024.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune’s Q3 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to Adaptimmune’s Q2 Financial and Business Update Conference Call. I would now like to turn the meeting call over to Ms. Juli Miller.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2023 Earnings Call Transcript
Juli Miller: Good morning, and welcome to Adaptimmune's conference call to discuss our first quarter 2023 financial results and business updates.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript
Operator: Welcome to Adaptimmune and TCR2 joint webcast to discuss their strategic combination announced earlier this morning.
5 High Growth UK Stocks to Buy
Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a biotechnology firm that develops tumor and cancer treatments. Some cancers that the firm is taking aim at include those of the lungs, head, and neck.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2022 Earnings Call Transcript
Juli Miller: Good morning and welcome to Adaptimmune's conference call to discuss our third quarter 2022 financial results and business update.
Is ADAP A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Adaptimmune Therapeutics plc (ADAP)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
